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Abstract
Deregulation of cyclin-dependent kinases 4 and 6 (CDK4/6) is highly prevalent in cancer; yet, inhibitors against these
kinases are currently used only in restricted tumour contexts. The extent to which cancers depend on CDK4/6 and the
mechanisms that may undermine such dependency are poorly understood. Here, we report that signalling engaging the MET
proto-oncogene receptor tyrosine kinase/focal adhesion kinase (FAK) axis leads to CDK4/6-independent CDK2 activation,
involving as critical mechanistic events loss of the CDKI p21CIP1 and gain of its regulator, the ubiquitin ligase subunit SKP2.
Combined inhibition of MET/FAK and CDK4/6 eliminates the proliferation capacity of cancer cells in culture, and enhances
tumour growth inhibition in vivo. Activation of the MET/FAK axis is known to arise through cancer extrinsic and intrinsic
cues. Our work predicts that such cues support cell division independent of the activity of the cell cycle-regulating CDK4/6
kinases and identiﬁes MET/FAK as a tractable route to broaden the utility of CDK4/6 inhibitor-based therapies in the clinic.
Introduction
The cyclin-dependent kinases CDK4 and CDK6 are core
components of the signal transduction network controlling
transition of cells from G1 (Gap1) phase of the cell cycle
into S (DNA synthesis) [1, 2]. Deregulation of this network
is a common event in cancer. Multiple oncogenic pathways
promote the synthesis of the activator D-type cyclins, and
gene mutation of regulators involved in limiting CDK4/6
activation is exceptionally frequent in all types of cancer
[3, 4]. The high frequency by which CDK4/6 regulation is
compromised in cancer implies that CDK4/6 deregulation is
a key event enabling cancer development, and by extension,
that inhibition of CDK4/6 could be a broadly applicable and
effective approach to cancer treatment [2, 5].
Several potent, selective small-molecule inhibitors tar-
geting CDK4/6 (CDK4/6is) have undergone clinical trials,
including palbociclib (PD0332991), abemaciclib (LY-
2835219) and ribociclib (LEE001) [6, 7], and gained reg-
ulatory approval in combination with hormonal therapy in
breast cancer [8–11]. However, evidence for clinical beneﬁt
has not been extended to other cancer types thus far, and
relapse under therapy is frequent in the approved indication
in breast cancer [9].
Activation of CDK4/6 requires their binding to D-type
cyclins, synthesised in response to mitogenic signals
[12, 13]. Bound to these cyclins, CDK4/6 phosphorylates
the retinoblastoma tumour suppressor protein (RB1), initi-
ating its inactivation. RB1 in its active form prevents the
transcription of genes required for S-phase entry, including
those encoding the E- and A-type cyclins involved in the
activation of the CDK4/6-related S phase cyclin-dependent
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kinase CDK2 [14]. In addition, RB1 promotes the ubiquitin-
dependent destruction of the SCF (SKP1–CUL1–F-box
protein) E3-ubiquitin-ligase substrate-recognition subunit
SKP2, stabilizing the CDK2 inhibitory proteins p21CIP1 and
p27KIP1, the degradation of which is SKP2 dependent
[15, 16]. Together, these activities limit CDK2 activation,
safeguarding licensed DNA synthesis and cell cycle transit.
Numerous reports describe situations where activation of
CDK2 is enabled in the absence of CDK4/6 activity and
show that CDK2 can drive cycle transit in the absence
CDK4/6 activity [17–24]. Hence, activation of CDK2,
independent of CDK4/6 activity, may limit the potency of
CDK4/6is in cancers, and identiﬁcation of signalling
required for CDK2 activation may yield information that
predicts CDK4/6 inhibitor response, or be exploited to
extend their efﬁcacy in cancer therapy.
Here, we report a mechanism-focussed screen aimed at
identifying signalling that enables CDK4/6-independent
CDK2 activation. We identify a prominent role of the MET
proto-oncogene tyrosine kinase receptor family and their
downstream effectors, the focal adhesion kinase (FAK)
family. Our data validate MET/FAK signalling as a
mechanism that enables CDK4/6-independent CDK2 acti-
vation and cell cycle transit, and we provide evidence for
the utility of MET or FAK inhibition as a means to improve
tumour response to CDK4/6 inhibition in vivo.
Results
Screening identiﬁes proteins required for CDK2
activation in CDK4/6-inhibited cells
To assess CDK2 activation in cells exposed to CDK4/6is, we
used a cell-based CDK2 reporter (GFP-PSLD) where a green-
ﬂuorescent protein (GFP) is fused to the CDK2-regulated
phosphorylated subcellular localisation domain (PSLD) of
human DNA helicase B [25]. Phosphorylation of the PSLD
by CDK2 exposes a nuclear export sequence, initiating
nuclear exclusion of the GFP fusion protein and accumulation
in the cytoplasm (Fig. 1a). We made use of human colorectal
carcinoma HCT116 cells (HCT116) that stably express GFP-
PSLD (HCT116-PSLD) [26]. Treatment of HCT116-PSLD
with siRNA targeting CDK2 or the CDK4/6i palbociclib
signiﬁcantly increased the fraction of cells, with pre-
dominantly nuclear ﬂuorescence (nuclear:cytoplasmic (nuc/
cyto) ﬂuorescence ratio >1.5), consistent with reliance of
reporter localisation on CDK2, and CDK4/6 activation
(Supplementary Fig. 1a–c). However, although palbociclib
treatment increased the percentage of cells with the nuclear-
localised CDK2 reporter, a considerable portion of cells with
loss of CDK4/6 activity, detected by the absence of RB1
phosphorylated at the CDK4/6-selective phosphorylation site
Ser780 (pRB1S780) [27], continued to contain a reporter with
predominant cytoplasmic localisation (Supplementary
Fig. 1d, e). This indicates CDK4/6-independent CDK2 acti-
vation. Unexpectedly, we observed that ablation of the
tumour suppressor TP53 reduced CDK2 control by palboci-
clib, even though the cells remained responsive to CDK4/6
inhibition, indicated by the reduction in cells containing
pRB1S780 (Supplementary Fig. 1f and 1g).
To identify signalling that permits CDK4/6-independent
CDK2 activation, we transfected HCT116-PSLD with a
library of small- interfering RNA (siRNA) pools targeting
kinases and kinase-relevant components and assessed the
ability of palbociclib to restrain CDK2 activation under
these conditions (Fig. 1b). Since we observed relaxed
CDK2 control following ablation of TP53 and because
functional TP53 loss is frequent in cancer, we included an
arm to the screen where we compromised TP53 expression
using TP53-targeted siRNA.
To identify siRNA pools that selectively decreased
CDK2 activity subject to palbociclib treatment, we com-
puted the sensitivity index (SI), which quantiﬁes the dif-
ference between the expected combined and measured
effects of two treatments [28, 29], in this case the effects of
speciﬁc siRNAs and the effect of CDK4/6 inhibition on
CDK2 activity. Ranking the SI values calculated using Z-
score statistics (Fig. 1c), we selected siRNA pools with Z
scores >2 for further analysis, yielding 30 pools that selec-
tively decreased CDK2 in combination with CDK4/6 inhi-
bition in HCT116-PSLD cells, and 23 in HCT116-PSLD
with compromised TP53 expression.
Most siRNA pools identiﬁed in TP53-compromised
HCT116-PSLD cells decreased CDK2 activity also in
HCT116-PSLD. Conversely, less than half identiﬁed in
HCT116-PSLD decreased CDK2 activity in TP53-modiﬁed
cells (Fig. 1d). These results indicate differences in the
regulation of CDK2 in TP53-normal and TP53-impaired
backgrounds, but at the same time, highlight the opportunity
to enhance the dependence of CDK2 activation on CDK4/6
in cells, regardless of TP53 status.
MET/FAK signalling is required for CDK2 activation
in CDK4/6-inhibited cells
To mine for annotated pathways overrepresented amongst
the siRNA targets identiﬁed, we used the MetaCoreTM
GeneGO tool (Supplementary Tables 1 and 2). This
revealed as most signiﬁcantly enriched a well-connected
hub involving the MET proto-oncogene/hepatocyte growth
factor receptor (MET) and the closely related macrophage
growth factor receptor (MST1R/RON), along with ﬁbro-
blast growth factor receptor 3 (FGFR3) and their common
downstream signalling targets, the focal adhesion kinases
(FAK) PTK2 and PTK2B (Fig. 2a).
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Two or more distinct siRNAs targeting MET, MST1R,
PTK2 or PTK2B synergistically increased the percentage
cells with nuclear-localised PSLD-GFP following CDK4/6
inhibition (Fig. 2b), validating the involvement of MET and
FAK family members in enabling CDK4/6-independent
CDK2 activation in cells. Combined use of MET and
MST1R or PTK2 and PTK2B siRNA did not enhance the
outcome, suggesting an independent, rate-limiting con-
tribution of individual MET and FAK family kinases in this
context. Notably, treatment with chemical inhibitors
targeting either the MET or FAK family kinases synergis-
tically decreased CDK2 activity in combination with pal-
bociclib (Fig. 2c). The activity of network components
FGFR3, SRC and JAK did not conﬁrm with multiple oli-
gonucleotides (Fig. 2b). Hence, the involvement of these
components in enabling CDK4/6-independent CDK2 acti-
vation cannot be certain.
To assess if inhibition of MET enables CDK2 control by
enhancing the efﬁcacy of CDK4/6is to control CDK4/6, we
assessed loss of pRB1S780 (Fig. 2d) in HCT116-PSLD
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Fig. 1 Screen for proteins
permitting CDK2 activation in
cells with CDK4/6 inhibition.
a Schematic depicting
functioning of the CDK2
reporter GFP-PSLD. Modular
reporter structure, relationship
between subcellular distribution
of GFP and cell cycle phase, and
a representative image of
individual HCT116-PSLD with
low (GFP-PSLD nuc/cyto > 1.5)
or high (GFP-PSLD nuc/cyto <
1.5) CDK2 activity is shown.
HDHB, human DNA helicase B;
NES, nuclear export sequence.
b Screen outline and procedure
for hit identiﬁcation. c Z-score
ranking for siRNA pools in the
screen. Results for unperturbed
(siNT) and TP53-perturbed
(siTP53) conditions are shown.
Data points represent the mean
of n= 3 independent repeats;
siRNA pools with Z score > 2
marked in red. d Hierarchical
clustering of hits based on mean
(n= 3) sensitivity index values
(SI). Colours denote the nature
of interaction between the
siRNA pool and palbociclib:
red, synergistic; white, additive;
blue, antagonistic. siRNA target
genes on the right. (Related to
Supplementary Fig. 1)
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treated with individual and combined inhibitors. As
expected, we observed a signiﬁcant increase in the fraction
of pRB1S780-negative cells following CDK4/6 inhibition.
Conversely, MET inhibition did not signiﬁcantly increase
the fraction of pRB1S780-negative cells. Importantly, com-
bined inhibition of CDK4/6 and MET was no more effec-
tive at raising the fraction of pRB1S780-negative cells than
inhibition of CDK4/6 alone at any concentration tested.
Nevertheless, and in agreement with our earlier results,
combined inhibition of CDK4/6 and MET led to a
signiﬁcantly greater reduction of cells with active CDK2
than treatment with either inhibitor alone (Fig. 2e).
Chou–Talalay concentration-effect analysis [30] identiﬁed a
robust synergistic interaction between MET and CDK4/6
inhibition towards reducing CDK2 activity, returning the
combination index (CI) values well below 1 across the
concentration range tested (Fig. 2f), irrespective of TP53
status. Hence, MET inhibition cooperates with palbociclib
to control CDK2 activation but does not enhance the ability
of palbociclib to supress CDK4/6 activity.
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Fig. 2 Signalling involving
MET permits CDK2 activation
in cells with CDK4/6 inhibition.
a MetaCoreTM GeneGO analysis
identiﬁes a signalling network
engaging MET overrepresented
by hits. Interaction types: P,
phosphorylation; B, binding;
proteins targeted by a screen
identiﬁed siRNA pools in blue.
b, c Hit validation using
individual siRNAs (b) or
pharmacological inhibitors for
MET/MST1R (crizotinib or
foretinib) or PTK2/2B (PDN-
1186 or defactinib) (c). Data
depict SI score relating to loss of
CDK2 activity in combination
with CDK4/6 inhibiton, using
palbociclib, determined using
GFP-PSLD localisation. Data
are mean ± SD for n= 3
independent repeats. d, e
Concentration-effect analysis
depicting a change in the
fraction of cells with low CDK4/
6 activity, assessed using
automated microscopy analysis
of cells immunostained for
pRB1S780 (d) or low CDK2
activity, assessed based on GFP-
PSLD localisation (e) following
individual or combined
inhibition of CDK4/6, using
palbociclib, and MET, using
crizotinib. Data are mean ± SD
for three independent repeats.
****p ≤ 0.0001, nsp > 0.05, one-
way ANOVA comparing effects
across concentrations against
vehicle or comparing palbociclib
alone against palbociclib plus
crizotinib (d) and comparing
palbociclib alone or crizotinib
alone against palbociclib plus
crizotinib (e). f CI value plot
calculated from data in (e).
Fa= fraction affected
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Combined MET and CDK4/6 inhibition synergistically
affects tumour cell fate in vitro and reduces tumour
growth in vivo
Since MET inhibition synergised with CDK4/6 inhibition to
enable the control of CDK2, we tested if this treatment
would also synergise to enable other responses associated
with CDK4/6 inhibition. Inhibition of CDK4/6 is recog-
nised for its ability to trigger permanent cell cycle exit,
thought to underlie its anticancer activity [31]. To assess if
MET inhibition enhances permanent cell cycle exit subject
to CDK4/6 inhibition, we exposed cells for 5 consecutive
days to inhibitors, then quantiﬁed their ability to form
colonies by seeding equal numbers of live cells into the
inhibitor-free medium (Fig. 3). We initially measured the
response of HCT116, using two chemically unrelated
inhibitors of CDK4/6, palbociclib and abemaciclib, and two
chemically distinct inhibitors of MET family kinases, cri-
zotinib and foretinib (Fig. 3a–d), in accordance with best
practice [32].
Combinatorial treatment signiﬁcantly enhanced the
reduction in colony outgrowth compared with individual
inhibitors (p < 0.01, two-way ANOVA). Identical outcomes
were obtained for HCT116 with genomic deletion of the
TP53 gene (TP53–/–) [33] or isogenic HCT116 with func-
tional TP53 (TP53WT), and highly synergistic (SI ≥ 0.25) or
synergistic (SI > 0.1) interactions were observed, regardless
of inhibitor chemotype or combination partner (Fig. 3b–d).
Biomarker analysis at 24 h conﬁrmed that inhibitors appro-
priately modulated their respective targets (Fig. 3a). Thus,
pRB1S780 had decreased where CDK4/6is were used, while
MET autophosphorylated on Tyr1234/1235 (pMETY1234/5)
had decreased in cells exposed to the METis. As noted
previously, MET inhibition did not affect pRB1S780 phos-
phorylation, nor did CDK4/6 inhibition affect the MET-
activation state. Cooperativity between MET inhibition and
CDK4/6 inhibition in reducing colony-formation capability
was also observed in cell lines derived from other cancer
types, namely in the oestrogen/progesterone receptor-
positive MCF7 human breast carcinoma-derived cells
(MCF7) and in the KRAS-mutated A549 human lung
adenocarcinoma-derived cells (A549) (Fig. 3e, f).
Combined inhibition of MET and CDK4/6 also syner-
gised towards loss of Ki-67 expression (Fig. 4a–c and
Supplementary Fig. 2). Loss of Ki-67 is indicative of cell
cycle exit [34] and predicts the response to CDK4/6 inhi-
bition in preclinical models [7]. Combined inhibition of
CDK4/6 and MET for 5 days signiﬁcantly and coopera-
tively increased the percentage of HCT116 negative for Ki-
67, compared with treatment with single agents—irrespec-
tive of TP53 status (Fig. 4a)—yielding CI values well
below 1 across the concentration range tested (Supple-
mentary Fig. 2a).
Loss of Ki-67 in individual cells correlated with nuclear
localisation of the GFP-PSLD reporter in the same cells
(Supplementary Fig. 2b, c), supporting that reduction of
CDK2 activity and loss of Ki-67 are mechanistically linked.
Furthermore, different MET and CDK4/6i chemotypes
synergised to reduce the fraction of Ki-67-positive cells
within treated populations (Supplementary Fig. 2d), indi-
cating that the observed effect is robust and involves on-
target MET and CDK4/6 inhibition.
Importantly, MET and CDK4/6 inhibition synergistically
reduced Ki-67 expression across a set of cancer cell lines,
with diverse tissues-of-origin and genetic driver proﬁles
(Fig. 4b, c). Concentration-effect analysis conﬁrmed a
synergistic interaction for 10 out of 12 lines tested. Notable
exceptions were two RB1-mutated lines, the osteosarcoma
line SAOS2 and the cervical cancer cell line C-33A, where
combination treatment had additive or less than additive
effects (Fig. 4b, c), consistent with the notion that RB1 is a
critical downstream effector of CDK4/6 and that RB1 loss
renders cells unresponsive to CDK4/6is. Thus, combined
MET and CDK4/6 inhibition synergises broadly across
cancer histio- and genotypes. The absence of synergism in
RB1-mutated backgrounds identiﬁes RB1 activity as a cri-
tical component required for this synergistic interaction.
We also assessed if combined inhibition of MET and
CDK4/6 enhances or enables senescence by quantifying
senescence-associated β-galactosidase (SA−β-gal) in cells.
CDK4/6is induce cellular senescence, which is thought to
underlie the loss of clonogenic activity they induce
[3, 31, 35]. Using C12FDG, a β-galactosidase substrate with
green-ﬂuorescent reaction product permitting automated
quantitative analysis, we observed an overt increase in cells
with C12FDG ﬂuorescence with characteristic distribution in
the perinuclear region following treatment with the inhibitor
combination (Supplementary Fig. 3a, b). Combination-treated
cells displayed additional changes associated with cellular
senescence, including ﬂattened shape, enlarged nuclei and
increased cell size. Automated quantitative analysis conﬁrmed
a concentration-dependent increase in the fraction of cells
with above-baseline perinuclear green ﬂuorescence following
combined, compared with single-agent treatment with METis
and CDK4/6is (Fig. 4d), with concentration-effect analysis
conﬁrming a robust synergistic interaction for the expression
of this senescence marker (Supplementary Fig. 3c).
Finally, we evaluated cell proliferation activity using
cells modiﬁed to express the nuclear marker GFP-H2B to
track division by time-lapse microscopy (Supplementary
Fig. 3d–i). These experiments revealed a synergistic
reduction in duplication activity subject to combined inhi-
bition of MET and CDK4/6—irrespective of TP53 status.
Together, these results support the notion that MET
inhibition synergistically increased known cellular respon-
ses associated with CDK4/6 inhibition. Conversely, the
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results support a role for MET in preventing these responses
in cells treated with CDK4/6is, including responses that
predict antitumour response to CDK4/6 inhibition in vivo.
To test if CDK4/6 inhibition combined with MET inhi-
bition is a feasible strategy for cancer treatment in vivo, we
assessed the combined effect of crizotinib and palbociclib
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Fig. 3 CDK4/6 and METis
cooperate to incapacitate cell
reproduction. a–d Clonogenic
activity in HCT116 determined
120 h following inhibitor
exposure to inhibitors of CDK4/6
(palbociclib or abermaciclib) or
MET (crizotinib or foretinib).
Data for HCT116 TP53WT and
TP53–/– are shown. Inhibitor
response biomarkers pRB1S780
(for CDK4/6 activity) and
pMETY1234/5 (for MET activity)
(a), determined 48 h following
inhibitor addition. GAPDH
served as a loading control.
b–f Clonogenic activity
determined 120 h following
inhibitor exposure in MCF7 and
A549. Exemplary raw data (b, e),
and quantiﬁcation of clonogenic
survival (mean ± SD, n= 3
independent repeats) (c, d, f) is
shown. Palbociclib and crizotinib
were used at 450 nM,
abemaciclib and foretinib at
225 nM. †††: SI ≥ 0.25 (highly
synergistic), ††: 0.25 > SI ≥ 0.1
(synergistic), ****p ≤ 0.0001,
one-way ANOVA
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on the growth of human tumour xenografts in athymic mice.
Combined daily administration of 100 mg/kg (p.o.) crizo-
tinib and palbociclib was well tolerated in the mice (Sup-
plementary Fig. 3k), yielding sustained accumulation of
agents within tumour tissue (Fig. 4f) and modulation of
pRB1S780 and pMET Y1234/5 pharmacodynamic biomarkers
over a 24-h period (Fig. 4g).
Using this schedule, we treated mice bearing HCT116
TP53–/– tumour xenografts (Fig. 4e) with individual inhi-
bitors or their combination for 8 days, then followed them
for a further 5 days, when tumours in the control group
reached predetermined size limits. This analysis conﬁrmed
superior efﬁcacy of the combination, with statistically sig-
niﬁcant reduction in tumour burden compared with single-
agent treatment at the end of the observation period (p=
0.005 against palbociclib and p= 0.006 against crizotinib,
Student’s t test).
Together, these results provide evidence that MET
activity constitutes a resistance mechanism in vitro and
in vivo, reducing the tumour cell response to CDK4/6
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inhibition. Importantly, our ﬁndings indicate that combined
pharmacological inhibition of MET and CDK4/6 is a fea-
sible strategy able to improve tumour growth inhibition in
mice, indicating the potential of this combination for
clinical use.
Synergistic inhibition of CDK2 by MET and CDK4/6is
involves p21CIP1
To identify the mechanism by which MET and CDK4/6
inhibition synergise, we characterised activity and compo-
sition of the CDK2 complex in inhibitor-treated cells using
immunoprecipitation. These experiments conﬁrmed a sig-
niﬁcant reduction in CDK2 activity subject to combined
MET and CDK4/6 inhibition, determined by the ability of
the anti-CDK2 immunoprecipitates to yield phosphorylation
of substrate (GST-RB 763-928) in vitro (Fig. 5a, b, Sup-
plementary Fig. 4a–d).
The decrease in CDK2 activity was not accompanied by
a decrease in the amount of cyclin E1 (CCNE1) or a change
in the phosphorylation of CDK2 at Tyr15 (pCDK2Y15) or
Thr160 (pCDK2T160), known to confer negative and posi-
tive regulation of CDK2 activity, respectively [36] (Fig. 5a).
However, there was a signiﬁcant increase in the amount of
the CDK inhibitor protein (CDKI) p21CIP1 in precipitates
from cells treated with combined MET and CDK4/6i, as
compared with single-agent- or vehicle-treated cells.
Decreased CDK2 activity and the increased presence of
p21CIP1 in anti-CDK2 precipitates were consistently
observed in multiple tumour cell lines subject to combined
MET and CDK4 inhibition (Fig. 5a, c). Analysis of input
lysates revealed loss of pRB1S780 in samples with CDK4/6
inhibition and loss of pMETY1234/5 in samples with MET
inhibition (Fig. 5d), verifying single- agent activity and
conﬁrming that these proximal biomarkers and pathways
are independently modulated by the respective inhibitors,
regardless of cell background. Essentially identical results
were obtained in immunoprecipitations performed, using an
antibody for the CDK2-activating cyclin E (Supplementary
Fig. 4e–m). Together, these results conﬁrm that reduction of
CDK2 activity is a cooperative event caused by combined
inhibition of CDK4/6 and MET. They further identify
binding of p21CIP1 to the CDK2 complex as a potential
cause underlying the cooperative interaction of these
inhibitors.
To assess if the increased association of p21CIP1 with the
CDK2 complex links to increased p21CIP1 abundance, we
analysed lysate from treated cells using immunoblotting
(Fig. 5d). A progressive increase in p21CIP1 abundance was
seen between 24 and 48 h subject to combination treatment
(Fig. 5e, with quantiﬁcation in Supplementary Fig. 5a). This
increase in p21CIP1 was apparent in TP53–/– HCT116,
indicative that the upregulation of p21CIP1, a known target
transcriptionally activated by TP53, is TP53 independent.
We also examined the abundance of the two other members
of the CIP/KIP CDKI family, revealing an increase in
p27KIP1 at 48 h, but not at earlier times. No change in the
levels of p57KIP2 was observed (Fig. 5e and Supplementary
Fig. 5a).
We further assessed the level of the SKP1-cullin-F-box
ubiquitin ligase substrate-recognition subunit (SKP2),
involved in regulating the stability of CIP/KIP family
proteins. A clear reduction in SKP2, detectable at 24 h and
pronounced at 48 h, was seen following combined inhi-
bition of MET and CDK4/6 compared with vehicle-
treated HCT116 (Fig. 5e and Supplementary Fig. 5a). The
abundance of SKP2 was not affected by CDK4/6 or MET
inhibition alone. Combined MET and CDK4/6 inhibition
led to upregulation of p21CIP1 and loss of SKP2 in mul-
tiple other cell backgrounds (Fig. 5e, with quantiﬁcation
in Supplementary Fig. 5b, 5c), indicative that this
response is broadly observable. Together, these experi-
ments indicate that signalling through MET and CDK4/6
acts redundantly to downregulate the CDKIs p21CIP1 and
p27KIP1, and to upregulate their regulator SKP2, in turn
providing a potential explanation why combined inhibi-
tion of MET and CDK4/6 is required for the inhibition of
CDK2 and cellular proliferation capacity.
To evaluate if CIP/KIP family members are involved in the
synergistic control of CDK2, we depleted these CDKIs alone
or in combination using siRNA and assessed the effect of this
Fig. 4 MET and CDK4/6is cooperate to promote cell cycle exit and
tumour response in vivo. a Concentration-effect analysis depicting the
fraction of HCT116 with low Ki-67, determined using automated
microscopy analysis of cells stained with Ki-67 antibody MIB1. Cells
were treated with inhibitors for 96 h. Data represent means ± SD for n
= 3 independent repeats. b, c Effect of CDK4/6 and MET inhibition
on the Ki-67 labeling index across a cancer cell line panel. Cells were
treated with palbociclib and/or crizotinib for 96 h. CI value calculation
(b) and exemplary results (c) based on two or more independent
repeats run in duplicate each are shown. CI50, CI75 and CI90 denote CI
values at concentrations with 50, 75 or 90% of cells responding with
Ki-67 loss, respectively, na= fractional responses not achievable
within the inhibitor concentration range tested. The mutation status of
key oncogenic drivers is indicated for each cancer cell line. Data
represent mean ± SD for n= 2 independent repeats, run in duplicate
each. d Concentration-effect analysis depicting the fractional increase
in cells with high SA−β-gal assessed using automated microscopy of
cells reacted with a ﬂuorescencent substrate C12FDG. Data represent
mean ± SD for n= 3 independent repeats, run in triplicate each.
e HCT116 tumour xenograft volumes, relative to day 0, in control- and
inhibitor-treated mice (mean ± SD, n= 10). f Concentration of inhi-
bitors in tumour xenograft tissue (mean ± SD, n= 3 tumours).
g Modulation of biomarkers indicative of CDK4/6 (pRB1S780) and
MET (pMETY1234/5) activity in tumour xenograft tissue (mean ± SD, n
= 3 tumours). **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001; two-way
ANOVA comparing the effect size of a single agent against that of the
combination (a, c, d) or two-sided unpaired Student’s t test (e, f, g).
(Related to Supplementary Fig. 2 and Supplementary Fig. 3)
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on CDK2 control, using the localisation of the GFP-PSLD
reporter (Fig. 5f). These experiments positively identiﬁed
p21CIP1 as a critical mechanistic component in controlling
CDK2 by combined MET- and CDK4/6 inhibition. Thus,
transfection of cells with siRNA targeting CDKN1A (which
encodes p21CIP1) consistently prevented CDK2 control by the
combination. siRNA targeting CDKN1B (encoding p27KIP1)
and CDKN1C (encoding p57KIP2) alone or in combination
had no effect, despite evidence that the siRNAs effectively
depleted the CDKIs concerned (Fig. 5g). Similar results were
obtained in cells simultaneously transfected with TP53-tar-
geted siRNA, indicating a critical role of p21CIP1, regardless
of TP53 status.
CDK2 regulation by the MET- and CDK4/6i combina-
tion was also prevented following loss of RB family pro-
teins, RB1, RBL1 and RBL2 (Fig. 5h), consistent with the
known resistance to CDK4/6is of cells with functional RB
loss and indicative of a critical mechanistic role of RB
protein function in the control of CDK2 by combined MET
and CDK4/6 inhibition.
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Constitutive FAK activity abolishes cooperation
between METis and CDK4/6is
Our siRNA screen identiﬁed the FAK family kinases PTK2
and PTK2B, which are known MET effectors, as candidates
that facilitate CDK4/6-independent CDK2 activation.
Hence, we sought evidence if signalling through these
kinases is involved in the CDK4/6-independent CDK2
activation by MET and whether additional MET-engaged
signalling might play a role. MET and its close relative
MST1R connect to multiple effector pathways, amongst
them RAS/RAF/ERK, PI3K/AKT, SRC and STAT3, which
they activate in addition to signal transduction involving the
FAK/PTK family (Supplementary Fig. 6a).
While effectively blocking MET autophosphorylation
within the catalytic region (pMETY1234/5) and at the MET
multifunctional docking site (pMETY1349) and, further,
autophosphorylation of MST1R at Tyr1353 (pMST1RY1353)
(Supplementary Fig. 6b), treatment of HCT116 with METi
alone or combined with CDK4/6i did not affect the acti-
vation state of RAS/ERK, PI3K/AKT, SRC and STAT3,
indicated by unchanged levels of activated AKT
(pAKTS473), ERK1/2 (pERKT202/Y204), SRC (pSRCY416) and
STAT3 (pSTAT3Y705), most likely due to activation of
these pathways by signalling independent of MET. In
contrast, a clear reduction was seen in modiﬁcations sig-
nifying activation of PTK2 (pPTK2Y576/577 and pPTK2Y925)
and PTK2B (pPTK2BY402), documenting reduced signal
transmission through these kinases following MET inhibi-
tion. Together, the results identify FAK family activity as
critically dependent on MET in HCT116 and loss of FAK
family activation as a key change resulting from MET/
MST1R inhibition.
To obtain evidence if FAK family activation through
MET is involved in CDK4/6i-resistant CDK2 activation, we
generated HCT116 cells expressing a membrane-targeted,
constitutively active PTK2 variant, CD2-PTK2 (Fig. 6a).
Expression of CD2-PTK2 did not affect the ability of MET
inhibition to block MET receptor activity, or the ability of
CDK4/6 inhibition to block RB1 phosphorylation (Fig. 6a).
However, expression of CD2-PTK2 permitted sustained,
METi-resistant PTK2 activation, indicated by the presence
of pY576/577-phosphorylated CD2-PTK2 (Fig. 6a). Sig-
niﬁcantly, in cells expressing CD2-PTK2, the activity of
CDK2 in anti-CDK2 immunoprecipitates was unaffected by
combined inhibition of CDK4/6 and MET (Fig. 6b, c).
Furthermore, the increased association of p21CIP1 following
combined CDK4/6 and MET inhibition was abolished (Fig.
6b, d and Supplementary Fig. 6c–f).
Notably, expression of CD2-FAK reduced the ability of
combined CDK4/6 and MET inhibition to decrease colony
formation in HCT116 cells (Fig. 6e, f), irrespective of
TP53 status. It also reduced the increase in p21CIP1 and the
loss of SKP2, associated with combined MET and CDK4/6
inhibition (Fig. 6g and Supplementary Fig. 6g). Together,
these results indicate that reduction of FAK activity is key
to limiting CDK2 and clonogenic activity following from
combined MET and CDK4/6 inhibition in cells.
The ﬁnding that combined inhibition of the MET/FAK
and CDK4/6 axis can promote p21CIP1 accumulation in
HCT116 TP53–/– implies a mechanism for TP53-indepen-
dent generation of p21CIP1, conferred by inhibition of the
MET/FAK axis. Consistent with this, and regardless of
TP53 status, we observed a signiﬁcant increase in
CDKN1A mRNA (encoding p21CIP1) following combined
CDK4/6 and MET inhibition compared with control or
CDK4/6i-treated cells (Fig. 6h), which was abolished by the
expression of constitutively active PTK2. Notably, the level
of CDKN1A mRNA increased in cells treated with METi
alone, indicating that CDKN1A transcription is suppressed
by signalling through MET/FAK, independent of CDK4/6.
Together, these experiments identify FAK family activity as
a critical effector downstream of MET involved in preser-
ving CDK2 activity and clonogenic potential in cells
exposed to CDK4/6i. They further suggest TP53-
Fig. 5 Cooperative control of CDK2 by MET and CDK4/6i involves
p21CIP1. a–d Characterisation of CDK2 complex using anti-CDK2
immunoprecipitation. Data for HCT116, MCF7 and A549 are shown.
Cells were treated with 500 nM of inhibitors for 24 h (HCT116) or
48 h (MCF7 and A549). Representative immunoprecipitation kinase
assay (a), depicting in vitro-phosphorylated GST-pRB
763–928 substrate (p-substrate) reporting CDK2 activity, and total
substrate (GST) (upper), and abundance of co-precipitated p21CIP1,
total and phosphorylated CDK2 (pCDK2Y15, pCDK2T160) and cyclin E
(CCNE1) in the respective immunoprecipitations (lower). Quantiﬁca-
tion (mean ± SD, n > 2 independent repeats) of p-substrate (b) and co-
precipitated p21CIP1 (c) relative to levels in vehicle-treated cells, and
immunoblots of input lysate (d) assessing biomarkers pRB1S780 (for
CDK4/6 activity) and pMETY1234/5 (for MET activity) for samples
analysed in this ﬁgure. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.01, and ****p ≤
0.0001, two-way ANOVA assessing the effect size of a single agent
with effect size of their combination, aHCT116, bMCF7, and cA549.
†††SI ≥ 0.25 (highly synergistic) calculated using mean values.
e Representative immunoblots assessing levels of CIP/KIP family
CDKIs and SKP2 in cell lysates after treatment of cells with 500 nM
inhibitors. f CDK2 activity, assessed using GST-PSLD localisation, in
HCT116 after transfection with siRNA targeting CIP/KIP family
proteins with or without siRNA targeting TP53, followed by treatment
with 500 nM inhibitors for 24 h (mean ± SD, n= 3 independent
repeats). nsp > 0.05, **p ≤ 0.01, ***p ≤ 0.001, two-way ANOVA
assessing the effect size of a single agent against the effect size of their
combination. aUnperturbed (siNT), bTP53-perturbed (siTP53).
g Immunoblot documenting loss of CIP/KIP family proteins following
transfection with siRNA. h CDK2 activity, assessed using GST-PSLD
localisation, in HCT116 after transfection with siRNA targeting RB
family proteins or TP53. Data depict mean ± SD for three independent
repeats, nsp > 0.05, ***p ≤ 0.001, two-way ANOVA assessing the
effect size of a single-agent treatment against effect size of their
combination. aUnperturbed (siNT), bTP53-perturbed (siTP53), cRB-
perturbed (siRB1/L1/L2). GAPDH (d, e, g) served as a loading con-
trol. (Related to Supplementary Fig. 4 and 5)
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independent CDKN1A transcript accumulation as a candi-
date mechanism, by which inhibition of MET/FAK pro-
motes CDK4/6i-resistant CDK2 activation and cell cycle
activity.
SKP2 is the critical common target engaged by MET
and CDK4/6
In addition to the increase in p21CIP1, our earlier results
showed a loss of SKP2 following combined CDK4/6 and
MET inhibition (Fig. 5e and Supplementary Fig. 5). SKP2
mediates the degradation of p21CIP1 [37] and itself is tar-
geted for degradation involving RB1 [15, 16]. Therefore,
SKP2 loss may be the consequence of sustained RB1
activity, following from effective control of CDK2 activity
through p21CIP1. SKP2 loss may stabilise p21CIP1, synthe-
sised from a transcript that accumulates as a consequence of
inhibition of the MET/FAK axis.
To test if this model explains how METis and CDK4/6is
synergise, we used siRNA or inhibitors to ablate the rele-
vant components and assessed the effect of this on SKP2
loss and p21CIP1 accumulation (Fig. 7). Consistent with the
model, ablation of RB family proteins abolished SKP2 loss
and p21CIP1 accumulation, following combined MET and
CDK4/6 inhibition (Fig. 7a, with quantiﬁcation in
Supplementary Fig. 7a). Also, consistent with this model,
PTK2 ablation, or pharmacological inhibition of FAK
family activity using defactinib, was sufﬁcient to trigger
p21CIP1 accumulation but insufﬁcient to cause SKP2 loss,
for which additional inhibition of CDK4/6 was required
(Fig. 7b, quantiﬁcation in Supplementary Fig. 7b).
Unexpectedly, SKP2 loss—predicted to require MET
inhibition in order to yield upregulation of p21CIP1—yielded
p21CIP1 accumulation that was not further enhanced by
MET inhibition (Fig. 7c, quantiﬁcation in Supplementary
Fig. 7c). This result indicates that p21CIP1 transcript upre-
gulation caused by MET inhibition may not be essential for
p21CIP1 accumulation, at least under conditions where SKP2
is absent at the outset, and could indicate that MET/FAK
inhibition has involvement in promoting SKP2 loss, inde-
pendent from SKP2 degradation that it may enable by
cooperating with CDK4/6 inhibition towards RB1 activa-
tion. Consistent with this prediction, we found that MET
inhibition, further to increasing transcript levels for p21CIP1,
suppressed transcript levels for SKP2, which like the
increase in the p21CIP1 transcript, was counteracted by
constitutively active PTK2 (Fig. 7d). Also consistent with
this prediction, we found that SKP2 loss enabled palbociclib
to control CDK2 activation without additional MET inhi-
bition (Supplementary Fig. 7d).
Together, these data support a mechanistic model (Fig.
7e) in which SKP2 acts as a common target engaged by
MET and CDK4/6 and proposes FAK-driven SKP2 and
potentially p21CIP1 transcript regulation as mechanistic
events through which the MET/FAK axis confers a refrac-
tory response to CDK4/6 inhibition, and through which
MET inhibition synergises with CDK4/6 inhibition to
deliver increased anticancer activity.
Discussion
Widespread recognition exists that CDK2 activation is
associated with acquired resistance of cancer cells to CDK4/
6-targeting cancer therapeutics [21–23] and also that
CDK2 supports CDK4/6-independent proliferation during
organismal development [20]. However, the molecular
determinants that permit activation of CDK2 in these con-
texts have not been systematically sought. CDK4/6-selec-
tive inhibitors are now showing considerable promise in
patients with oestrogen receptor-positive breast cancer, yet
there is clear need to identify functions that drive resistance
in treatments involving these agents and that preclude their
broader use in other cancer types. Here, we report that
activation of the MET/FAK signalling axis leads to CDK4/
6-independent CDK2 activation, and constitutes a broadly
applicable druggable means to improve the response of
cancers to CDK4/6-targeted therapies.
Fig. 6 Constitutive PTK2 activity impairs cooperation between MET
and CDK4/6is. a–d Characterisation of CDK2 complexes in HCT116
expressing constitutively active CD2-PTK2. a Immunoblot of input
lysate documenting CD2-PTK2 expression and modulation of drug
response biomarkers pRB1S780 (for CDK4/6 activity) and pMETY1234/5
(for MET activity). C denotes control cells without CD2-PTK2
expression, < identiﬁes a signal for cell-intrinsic PTK2, * identiﬁes
CD2-PTK2. b Representative immunoprecipitation kinase assay.
Abundance of in vitro-phosphorylated GST-pRB 763-928 substrate
(p-substrate) reﬂecting CDK2 activity and total substrate (upper),
abundance of p21CIP1 and CDK2 (lower) in the respective immuno-
precipitations. c Mean abundance of p-substrate and d mean abun-
dance of co-precipitated p21CIP1 relative to vehicle-treated cells. Data
(c, d) represent mean ± range for two independent repeats. Cells were
treated for 24 h using 500 nM of each inhibitor. *p ≤ 0.05, **p ≤ 0.01,
two-way ANOVA assessing the effect size of combination treatment
between control and CD2-PTK2-expressing cells and nsp > 0.05, two-
way ANOVA assessing the effect size of a single agent against effect
size of their combination in cells expressing CD-PTK2. e–f Clono-
genic survival of cells expressing constitutively active CD2-PTK2. e
Exemplary raw images and f quantitative assessment representing
mean values ± SD for three independent repeats. Cells were treated
with 500 nM inhibitors for 120 h. *p ≤ 0.05, **p ≤ 0.01, two-way
ANOVA assessing effect size of combination treatment between
controls and CD2-PTK2-expressing cells. g Representative immuno-
blots assessing the abundance of CIP/KIP family proteins and SKP2 in
HCT116, with constitutively active CD2-PTK2. Cells were treated
with 500 nM inhibitors. h RT/qPCR assessing CDKN1A mRNA
levels. Cells were treated with 500 nM inhibitors for 24 h. Data are
mean values ± SD of three independent repeats; ****p ≤ 0.0001, nsp >
0.05, one-way ANOVA. GAPDH (a, g) served as a loading control.
(Related to Supplementary Fig. 6)
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Fig. 7 SKP2 is the critical
function engaged by MET and
CDK4/6. a–c Representative
immunoblots assessing levels of
p21CIP1, p27KIP1 and SKP2
protein in cells treated with
siRNA against RB family
proteins (RB) (a), siRNA
against PTK2 or the FAK
inhibitor defactinib (900 nM)
(b) or siRNA targeting SKP2
(c). Data for TP53WT and TP53–/
– HCT116, MCF7 and A549 are
shown. Cells were treated with
500 nM METi crizotinib and/or
CDK4/6i palbociclib. GAPDH
served as a loading control.
d RT/qPCR assessing CDKN1A
mRNA in HCT116 treated with
500 nM inhibitors for 24 h. Data
are mean values ± SD for three
independent repeats; **p ≤ 0.01,
one-way ANOVA comparing
the effect of vehicle vs.
treatment. e Model, detailing the
consequence of combined
CDK4/6- and MET inhibition.
Grey box indicates an active
node and red indicates active
signalling. (Related to
Supplementary Fig. 7)
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MET is widely expressed in epithelial and endothelial
cells, including cancers derived from these tissues, and may
be activated in cancer cells through mutation. However,
more frequently, MET signalling is activated by the hepa-
tocyte growth factor/scatter factor, HGF, produced by
adjacent mesenchymal tissues, including stromal compo-
nents of cancers [38–40].
We identiﬁed the MET/FAK axis based on a functional
genetic screen, using CDK2 activity as a mechanism-based
endpoint. Apart from the MET/FAK axis, which we
mechanistically explore in our work, the screen yielded
other hits without known links to MET and/or FAK sig-
nalling, including ontology noted previously for synergistic
interaction with catalytic inhibition of CDK4/6, such as
RPS6KA6 and BRAF, inhibitors of which increase the
response of cancer cells to CDK4/6 inhibition [2, 21, 41].
Unexpectedly, our screen indicates that TP53 status affects
the spectrum of molecular functions required to support
CDK4/6-independent CDK2 activation, with requirement of
certain functions, including, e.g. RPS6KA6, conﬁned to
TP53-normal backgrounds. While further validation is
required, these observations suggest that the TP53 status
could determine the efﬁcacy of certain combinations.
In addition to MET, the screen identiﬁed FAK family
kinases, that our subsequent work validates as a critical
component by which MET elicits CDK4/6-independent
CDK2 activation. Our experiments involving a con-
stitutively active form of the FAK family kinase PTK2
demonstrate that FAK activity is sufﬁcient to elicit sig-
niﬁcant CDK4/6i tolerance. In the experimental models
examined, MET scores as a key determinant responsible for
FAK family activation, as indicated by the robust reduction
of activated FAK species pPTK2Y576/577, pPTK2Y925 and
pPTK2BY402 following treatment with METi. However,
FAK family kinases can be activated by other routes—
including by MET-unrelated tyrosine kinase receptors and
their activators, and by extracellular matrix signalling
involving integrins [42]. The broad range of signalling able
to engage FAK highlights the possibility that CDK4/6i
resistance involving FAK could be caused in cancer patients
by events other than MET activation.
Our work indicates that sustained expression of the
ubiquitin ligase subunit SKP2, which promotes the degra-
dation of p21CIP1 as well as that of other CIP/KIP CDKIs, is
a key mechanism by which MET/FAK supports activation
of CDK2. Our experiments show that signalling through
this axis increases the steady-state level of SKP2 mRNA.
The involvement of FAK in the regulation of SKP2 and
p21CIP1 was previously noted. For example, inhibition of
FAK through enforced expression of FAK-related non-
kinase (FRNK) or dominant negative FAK (Tyr397Phe)
reduced the expression of SKP2 protein in human and rat
endothelial cells [43, 44]. Furthermore, inhibition of FAK
by FRNK, FAK (Tyr397Phe) or small-molecule inhibitors
resulted in elevated p21CIP1 transcript and protein in normal
human ﬁbroblasts, smooth muscle cells or glioblastoma-
derived cells [43, 45, 46]. These results independently
support our observations that FAK family kinases regulate
SKP2 and the CIP/KIP inhibitor p21CIP1. How MET/FAK
signalling affects SKP2 transcript levels is currently not
known, but given the involvement of this signalling axis in
CDK4/6i resistance, this is clearly an important aspect to be
addressed in future studies.
Our work indicates that MET inhibition signiﬁcantly
enhances therapeutic inhibition of growth by CDK4/6is in
preclinical models of human cancer. Furthermore, our
results identify FAKs as key downstream components in
this context. The recognised ability of cancer-relevant,
MET-independent signalling routes to activate FAKs make
this kinase family, or druggable targets downstream of it,
potentially more attractive therapeutic targets than MET for
use in combination with CDK4/6 inhibition. FAK family
kinases are a recognised drug target in cancer, and inhibitors
targeted to the ATP-binding pocket of their kinase domain
have entered clinical trials, albeit with limited single-agent
efﬁcacy in patients thus far [47–49]. Our results suggest an
opportunity for use of FAK inhibitors in conjunction with
CDK4/6is as a potentially powerful approach to improve
the outcome for patients treated with CDK4/6-targeted
therapies or to expand the current, approved indications
through mechanism-based targeted combinations.
Methods
Cell culture, chemicals and antibodies
HCT116 TP53–/– and isogenic HCT116 TP53wt cells were
provided by the Vogelstein laboratory (John Hopkins Uni-
versity, Baltimore, MD). Other cell lines were acquired
from the American Type Culture Collection (ATCC).
HCT116-PSLD are described in ref. [26]. Cells expressing
CD2-PTK2 were constructed by lentiviral transduction
using pLV-neo-CD2-FAK [50]. Inhibitors used were pur-
chased from Selleck Chemicals. Antibodies and siRNAs
used are summarised in supplementary materials.
RNAi screens
Screens used the kinase-covering component of the
Dharmacon siGENOME SMARTpoolTM library. Library
pools were mixed at an equimolar ratio with SMART-
poolTM oligonucleotides targeting TP53 or non-targeting
oligonucleotide, then reverse transfected at a combined
concentration of 20 nM into HCT116-PSLD, seeded in
96-well plates. Transfected cells were incubated for 24 h
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prior to treatment with CDK4/6i palbociclib (450 nM) or
vehicle for 24 h. Plates were ﬁxed in 4% formaldehyde,
then stained with Hoechst 33342 DNA dye and imaged
using an INCell Analyzer 3000 (GE Healthcare) or an
Opera (Perkin-Elmer) high-content imager platform. Data
for a minimum of 2000 cells per condition were collected.
Data were processed using CellProﬁler open-source image
analysis software [51].
In vivo human tumour xenograft studies
All animal work was carried out under UK Home Ofﬁce
regulations in accordance with the Animals (Scientiﬁc
Procedures) Act 1986 and according to United Kingdom
Co-ordinating Committee on Cancer Research guidelines
for animal experimentation [52] with local ethical approval.
For therapy studies, mice were treated daily for a con-
tinuous period, followed by observation, until tumour size
in the control group approached predetermined humane size
limits. For pharmacodynamic studies, tumour samples were
collected at 24 h post administration.
Further method details are provided in the
supplementary text.
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